my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
BioAlliance Pharma (Euronext Paris: Code Isin FR0010095596 - BIO) is a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections. To attack the challenge of resistance, the company has more
BioAlliance Pharma SA announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis. The objectives of this first phase I trial were to evaluate the safety of intratumoral electrotransfer of AMEP® bioth more
BioAlliance Pharma SA announced the extension of its ongoing clonidine Lauriad™ phase II clinical trial in chemoradiation therapy induced oral mucositis in patients with head and neck cancer to Germany and Spain. The expansion of the trial (currently ongoing in France) to two new countries will rai more
BioAlliance Pharma SA announced the update of its preliminary positive survival data with Livatag® (doxorubicin Transdrug™). Livatag® is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. Livatag® was granted an orphan drug status in Europe and in the United more
Printable version About us Our Products R & D Partnerships People Investor & Media Management Committee Board of Directors Scientific Advisory Boards Qualified Pharmacist Scientific Profiles Careers Board of Directors Philippe ARCHINARD - - - Dr. Jean-Pierre BIZZARI - - - Pr. Christian BRECHOT - - more
providing special products to special people Home About Us Corporate Strategy Organization Management Experience Supervisory Board Investors Products Dantrium ® / Dantrolen ® Savene ® MuGard™ Xerotin ® PROTHER™ Business Development Partnerships Careers Press Room Contacts Legal Disclaimer 01/09/2011 more
French | English Home The Group's Products R&D Business development Investors Press room Specialising in cancer and supportive care – pathologies associated with cancerology, chemotherapy and radiotherapy complications and opportunistic infections that develop in immunocompromised patients – BioAlli more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
